Synthesis and Biological Activity of Metabolites of the Antidiabetic, **Antihyperglycemic Agent Pioglitazone**

Steven P. Tanis,^{*,†} Timothy T. Parker,[†] Jerry R. Colca,[‡] Roberta M. Fisher,[‡] and Rolf F. Kletzein[‡]

Departments of Discovery Chemistry and of Endocrine Pharmacology and Metabolism, Upjohn Laboratories, Pharmacia and Upjohn, Inc., Kalamazoo, Michigan 49001

Received August 5, 1996[®]

Pioglitazone (5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione, 2) is a prototypical antidiabetic thiazolidinedione that had been evaluated for possible clinical development. Metabolites 6-9 have been identified after dosing of rats and dogs. Ketone 10 has not yet been identified as a metabolite but has been added to the list as a putative metabolite by analogy to alcohol **6** and ketone **7**. We have developed improved syntheses of pioglitazone (**2**) metabolites 6-9 and the putative metabolite ketone 10. These entities have been compared in the KKA^y mouse model of human type-II diabetes to pioglitazone (2). Ketone 10 has proven to be the most potent of these thiazolidinediones in this *in vivo* assay. When **6**–**10** were compared *in* vitro in the 3T3-L1 cell line to 2, for their ability to augment insulin-stimulated lipogenesis, 10 was again the most potent compound with 6, 7, and 9 roughly equivalent to 2. These data suggest that metabolites 6, 7, and 9 are likely to contribute to the pharmacological activity of pioglitazone (2), as had been previously reported for ciglitazone (1).

Introduction

Non-insulin-dependent diabetes mellitus (NIDDM) is a metabolic disease characterized by a reduction in the response of the peripheral target tissues to insulin and the inability of pancreatic insulin reserves to overcome this reduced response.^{1,2} The incidence of the disease has been estimated to be approximately 5% of the population and to contribute in excess of 105 billion dollars to the health care costs (approximately 15% of the total health care cost) in the United States.³ Current opinion holds that although there may be many genetic factors involved and pancreatic dysfunction is a prequisite for the clinical expression of NIDDM, the trigger for the development of NIDDM is the reduced responsiveness of the peripheral tissues to insulin, or insulin resistance. Thus, there is reason to believe that improvement of insulin sensitivity of the target tissues may not only reduce the consequences of established disease but actually prevent the development of NID-DM.^{4,5} A successful therapy of this modality would likely have a substantial impact on health care costs.^{6,7}

Although the biochemical basis for insulin resistance remains to be defined, thiazolidinediones and related analogs have been identified which either prevent or protect against experimental insulin resistant states which occur genetically or are induced by dietary or hormonal means.⁸⁻¹² These compounds appear to augment the insulin-signaling cascade, although the mechanism by which these compounds exert their effects on the sensitivity of target cells to insulin also remains to be elucidated.9-14 Several studies have shown that analogs of this class, in addition to augmenting the insulin-signaling cascade in insulin target cells, increase the rate of differentiation of preadipocytes in culture.¹⁵ Hence, it is possible to evaluate the biological activity of these compounds in vivo in animals exhibiting reduced insulin sensitivity and in vitro using cell models for adipocyte differentiation.

Most productive has been the use of murine models of insulin resistance which have given rise to the discovery of compounds such as the thiazolidinedione ciglitazone (1). $^{7,16-17}$ Analysis of the structure-activity relationship of related compounds has given rise to at least four entities that are or have been in clinical development: pioglitazone (2)18 (Takeda Chemical Industries, Inc./Upjohn), troglitazone (3)19 (Sankyo and Parke-Davis), englitazone (4)^{20,21} (Pfizer), and BRL 49653 (5)²² (SmithKline Beecham).

Pioglitazone (5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione, 2) is a prototypical antidiabetic thiazolidinedione that has been evaluated for possible clinical development (vide supra). In the course of characterizing this compound, the metabolic fate of pioglitazone in laboratory animals was investigated.²³⁻²⁵ Metabolites 6-9 (Figure 2) have been identified after the dosing of rats and dogs. Ketone 10 (Figure 2) has not yet been identified as a metabolite but has been added to the list as a putative metabolite by analogy to alcohol 6 and ketone 7. We wished to develop improved syntheses of compounds $6-10^{26}$ in order to evaluate their biological profile in vitro and in vivo. These data would be of value as they would aid in the interpretation of the *in vivo* activity of pioglitazone (2). That is, is there a portion of the antihyperglycemic activity and duration of action of 2 which might be more appropriately attributed to its metabolites? These studies might also serve as a prelude to the possible selection of a metabolite of pioglitazone (2) as a second-generation thiazolidinedione clinical candidate. Such a compound might have an improved half-life and a simpler metabolic pattern and fate when compared to 2.

Chemistry

We elected to pursue the synthesis of metabolites 6-8from a common pyridine precursor, methyl 6-methylnicotinate, to maximize the utility of common precursors. In order to minimize the impact of an increase in the

Department of Discovery Chemistry.

Department of Endocrine Pharmacology and Metabolism.
 Abstract published in Advance ACS Abstracts, November 15, 1996.




Figure 1. Representative thiazolidinedione antihyperglycemic agents 1-5.





Figure 2. Rat and dog metabolites **6**–**9** of pioglitazone (**2**) and putative metabolite (**10**).

Scheme 1^a




^a (a) NaH, EtOAc; (b) 10% aqueous H₂SO₄, Δ ; (c) NaBH₄; (d) NaH, (e) MOMCl; (f) 37% aqueous CH₂O, 170 °C; (g) DEAD, Ph₃P, 4-HOPhCHO; (h) 2,4-thiazolidinedione, piperidine, EtOH, Δ ; (i) NaBH₄, CoCl₂, dimethylglyoxime; (j) 2 N aqueous HCl, Δ .

number of steps in the terminal stage of a linear synthesis, we planned to pursue three separate routes to the target metabolites. One each for alcohol $\bf 6$ and ketone $\bf 7$ and a third for acid $\bf 8$.

Our synthesis of **6** is presented in Scheme 1. Methyl 6-nicotinate was treated with sodium hydride and ethyl acetate to give the related β -keto ester which was immediately decarboxylated (aqueous H₂SO₄, Δ) to afford 6-methyl-3-acetylpyridine (**11**)²⁷ (48%). The ketone was smoothly reduced with sodium borohydride

(EtOH, 0 °C), leading to the known pyridylethanol **12** in 90% yield.²⁶ Treatment of the pyridylethanol **12** with sodium hydride (DMF, 0 °C) formed the sodium salt. The mixture was cooled in a dry ice/2-propanol bath, chloromethyl methyl ether was added, and the reaction was then quenched at 0 °C to furnish **13** in 79% distilled yield. A mixture of methylpyridine **13** and 1.05 equiv of 37% aqueous formaldehyde was heated to 170 °C in a sealed (Teflon screw cap), thick walled glass tube (6 h) to give 27% of **14**^{18,26,27} and 57% of recovered **13**. The





^{*a*} (a) Ethylene glycol, pTsOH (1.25 equiv), toluene, Δ ; (b) 37% aqueous CH₂O, 150 °C; (c) DEAD, Ph₃P, 4-HOPhCHO; (d) 2,4-thiazolidinedione, piperidine, EtOH, Δ ; (e) NaBH₄, CoCl₂, dimethylglyoxime; (f) 2 N aqueous HCl, Δ .

connection of **13** to the central aryl ring was accomplished *via* a Mitsunobu coupling²⁸ between **14** and 4-hydroxybenzaldehyde to give **15** in reproducible 60-65% yields.

Aldehyde 15 was then subjected to "standard" Knoevenagel condensation conditions as defined by Takeda^{18,26} (EtOH, piperidine (0.2 equiv), 2,4-thiazolidinedione (1.5 equiv)) to provide a 58% yield of the target protected dehydropioglitazone metabolite 17. The completion of the synthesis endeavor required the selective reduction of the benzylidenethiazolidinedione, with preservation of the benzylic C-O bond, followed by deprotection to give 6. Toward that end we utilized a modified conjugate reduction protocol²⁹ of Pfaltz³⁰ to reduce the double bond. A stirring mixture of CoCl₂--6H₂O and dimethylglyoxime in THF/H₂O containing aqueous NaOH was treated with NaBH₄ to produce a deep blue mixture. The reducing mixture was cooled in an ice-water bath and olefin 16 was added. The reaction mixture was carefully monitored by TLC, and the reaction was quenched upon the disappearance of olefin 16 (3 h) to give compound 17 (61%). The MOM ether was removed by treatment of a suspension of 17 in MeOH with 2 N aqueous HCl at reflux for 2 h, to give 6 in 98% yield.


Our next target, **7**, was prepared as outlined in Scheme 2. 6-Methyl-3-acetylpyridine (**11**) was treated with ethylene glycol and 1.25 equiv of pTsOH in toluene (Δ , H₂O) to give ketal **18** in 92% yield. The reaction of **18** with 1.0 equiv of 37% aqueous formaldehyde at 150 °C for 5 h afforded a 24% yield of **19** with 62% of **18** recovered. Pyridylethanol **19** was smoothly coupled (Ph₃P, DEAD) with 4-hydroxybenzaldehyde to provide **20** (55%) which readily underwent condensation with 2,4-thiazolidinedione to give the dehydro ketal **21** (56%). Reduction^{29,30} as before (CoCl₂, NaBH₄, dimethylgly-oxime) furnished **22** (96%), which led to **7** after ketal hydrolysis with 2 N aqueous HCl (98%).

Having successfully prepared quantities of **6** and **7**, we turned our attention to the preparation of the carboxylic acid metabolite **8**. As a result of the acid stability of **2** as well as the acid stability of the metabolites prepared to date (**6**, **7**), we designed a synthetic path to **8** which would unmask the terminal -COOH in an acid-mediated nitrile hydrolysis step. The synthesis of acid **8** is presented in Scheme 3. Methyl 6-methylnicotinate was reduced with LAH/THF to give pyridylmethanol **23** (85%) which was then protected as the related MOM ether **24** (MOMCl, NaH, DMF, -20

°C; 73%). Ether 24 was treated with 37% aqueous formaldehyde and heated in a glass tube in a 150 °C oil bath for 5 h to afford a 29% yield of (hydroxyethyl)pyridine **25** and 60% of recovered pyridine **24**. Pyridine 25 was then coupled with 4-hydroxybenzaldehyde, in Mitsunobu fashion, to give aldehyde 26 in 58% yield. The MOM ether was removed by treatment of 26 with 2 N aqueous HCl in methanol to give 27. Alcohol 27 could be transformed to nitrile **28** via the intermediacy of an unisolated (chloromethyl)pyridine, prepared according to the procedure of Carlson *et al.*³¹ In the event, alcohol 27 was treated with thionyl chloride in refluxing chloroform to furnish the related chloride which was immediately reacted with KCN in DMF to provide a 61% yield of nitrile 28. The condensation of 28 with 2,4-thiazolidinedione (piperidine, EtOH) was uneventful, leading to 29 in 65% yield. The reduction of benzylidenethiazolidinedione 29 proved to be somewhat problematic. When the reaction conditions which had been successfully employed in the preparations of 6 and 7 (CoCl₂, NaBH₄, dimethylglyoxime) were extended to the reduction of 29, the results were poor or no doublebond reduction occurred. We finally resorted to a modification of these conditions²⁹ (CoCl₂, NaBH₄, 2,2'dipyridyl) to obtain an acceptable 56% yield of 30. Completion of the synthesis of 8 was realized after the exposure of 30 to refluxing 4 N aqueous HCl to give a 72% yield of the target metabolite 8.


The remaining two targets, 9 and the putative metabolite 10, were synthesized as described in Scheme 4. Pioglitazone (2) was oxidized (MCPBA) to give the related N-oxide 31 in 96% yield. N-Oxide 31 was then submitted to a modification of the procedure of Boekelheide³² to effect the desired rearrangement. Toward that end, pioglitazone N-oxide (31) was treated with trifluoracetic anhydride (TFAA) in refluxing methylene chloride for 2 h. After cooling to room temperature, the solvent, trifluoroacetic acid, and excess TFAA were removed in vacuo, and the residue was dissolved in THF. To the resulting solution was added saturated aqueous NaHCO₃ until CO₂ evolution ceased to give 9 in 74% yield. The putative metabolite 10 would be realized upon oxidation of alcohol 9. After considerable experimentation, we settled on a modified DMSO oxidation reported by Taber³³ for the conversion of **9** to **10**. A solution of 6 in DMSO and methylene chloride was cooled in an ice-water bath and treated in order with P_2O_5 and triethylamine to give **10** (crude) as a light yellow solid which required simple chromatographic

Scheme 3^a



^{*a*} (a) LAH, THF; (b) NaH; (c) MOMCl; (d) 37% aqueous CH₂O, 150 °C; (e) DEAD, Ph₃P, 4-HOPhCHO; (f) 2 N aqueous HCl, MeOH; (g) SOCl₂, CHCl₃, Δ ; (h) KCN, DMF; (i) 2,4-thiazolidinedione, piperidine, EtOH, Δ ; (j) NaBH₄, CoCl₂, 2,2'-dipyridyl; (k) 4 N aqueous HCl, Δ .

Scheme 4^a




a (a) MCPBA, CH₂Cl₂; (b) TFAA, CH₂Cl₂, Δ; (c) aqueous NaHCO₃, THF; (d) DMSO, P₂O₅, Et₃N, CH₂Cl₂.

purification (88% purified yield). With the target metabolites in hand, we proceeded to evaluate their activity as potential antihyperglycemic agents in the KKA^y mouse model of type-II diabetes³⁴ and the facility with which they enhance the insulin-regulated differentiation of 3T3-L1 cells to adipocytes.¹⁵

Results and Discussion

Antihyperglycemic activity was determined in obese, hyperglycemic, hyperinsulinemic, insulin resistant KKA^y mice.^{18,34} These mice are a cross between glucose intolerant black KK female mice and obese yellow male A^y mice. Animals were grouped into treatment and control groups (n = 6) through pretest blood glucose measurements by bleeding from the retroorbital sinus with glucose levels measured with an Alpkem glucose autoanalyzer.³⁵ Treatment groups had the selected compound administered as a food admixture at 100 mg/ kg for 4 days. The glucose level for the treated group (T) over the control group (C) was utilized to determine the antihyperglycemic activity of the test compounds. Pioglitazone (**2**) was dosed at 100 mg/kg as the positive control, and results are reported as a T/C value. A Table 1. Antihyperglycemic Activity of Compounds ${\bf 2}$ and ${\bf 6-10}$



no.	R_1	X	antihyperglycemic assay in KKA ^y mice T/C
2	CH ₂ CH ₃	CH_2	0.49
6	CH(OH)CH ₃	CH_2	0.74
7	COCH ₃	CH_2	0.74
8	CH ₂ CO ₂ H	CH_2	0.91
9	CH ₂ CH ₃	CHOH	0.78
10	CH ₂ CH ₃	CO	0.39

compound with a T/C value of 0.85 is considered active in this model of diabetes.

Metabolites **6**–**9** and pioglitazone (**2**) were examined in the KKA^y mouse as a measure of their ability to function as antihyperglycemic agents. These results are presented in Table 1. Pioglitazone (**2**), the positive control, effectively lowered blood glucose in the KKA^y mice providing a T/C = 0.49. Carboxylic acid **8** is




Figure 3. Thiazolidinedione-mediated augmentation of insulin-stimulated lipogenesis *in vitro*; [¹⁴C]acetate incorporation into lipid in 3T3-L1 cells.

inactive as an antihyperglycemic agent in the KKA^y mouse, exhibiting a T/C = 0.91. The hydroxylated metabolites **6** and **9** and ketone **7** behaved similary in this assay, providing T/C values of 0.74, 0.78, and 0.74, respectively, an indication of modest antihyperglycemic activity. By comparison, ketone **10** exhibited antihyperglycemic activity in the KKA^y mice, with a T/C = 0.39. A perusal of these results does not immediately provide a rationale for this activity based upon position of metabolism, polarity, or electronic effects.

As a second measure of activity, we examined the ability of thiazolidinediones 6–10 to augment insulinstimulated lipogenesis in vitro. The 3T3-L1 cell line, in the presence of the appropriate hormonal signals, undergoes differentiation from a fibroblastic adipoblast to a mature adipocyte capable of carrying out insulinregulated lipogenesis.¹⁵ Pioglitazone (2) has been reported to markedly enhance the insulin-regulated differentiation of 3T3-L1 adipocytes.¹⁵ 3T3-L1 cells were staged to differentiate by incubation for 48 h in medium containing 1 µM dexamethasone and 0.5 mM 3-isobutyl-1-methylxanthine. Confluent cells were then incubated in Dubelco's modified Eagle's medium containing 5% fetal calf serum with insulin (150 nM) with and without added thiazolidinedione (0–10 μ M). Forty-eight hours after time 0 (addition of insulin and compound), the cells received a 1 h pulse of [14C]acetate and were then harvested. The ability of the target metabolites 6-9, and the putative metabolite 10, to enhance insulinregulated differentiation of 3T3-L1 was measured versus pioglitazone (2) as a positive control utilizing the incorporation of [14C]acetate into lipid (Figure 3) as the determinant of activity. Lipogenesis in the 3T3-L1 cells was measured, as this is the index of the fully differentiated phenotype of the adipocyte and pioglitazone (2) has been previously shown¹⁵ to enhance the rate of insulin-stimulated lipogenesis in these cells. Figure 3 presents these results.

Pioglitazone (2) produced an augmentation of insulinstimulated lipogenesis in a dose-dependant fashion which resulted in a ¹⁴C incorporation of *ca.* 92 000 dpm at 10 μ M **2**. As might have been expected from the results in the KKA^y mouse model, compounds **6**, **7**, and **9** were active in the 3T3-L1 cell assay. At the highest dose (10 μ M) they were virtually indistinguishable from pioglitazone (**2**). However these metabolites were much more efficient than **2** in stimulating lipid synthesis at the 3 μ M dose. Carboxylic acid **8** was quite poor in its ability to stimulate lipid synthesis at all drug levels. Ketone **10** provided high levels of [¹⁴C]acetate incorporation into lipid at 1 μ M (87 000 dpm), 3 μ M (106 000 dpm), and 10 μ M (108 000 dpm).

The *in vitro* activities of **2**, **8**, and **10** can be favorably compared with their *in vivo* activity in KKA^y mice in that **10** is more potent than **2** and **8** is essentially inactive. The comparison of alcohols **6** and **9** and ketone **7** with pioglitazone (**2**) and ketone **10** are more difficult to make, and perhaps these *in vivo* data reflect differences in biodistribution and pharmacokinetics in the mouse model.

In conclusion, we have developed improved syntheses of pioglitazone (2) metabolites 6-9. We have also prepared the putative metabolite ketone 10. These entities have been compared to pioglitazone (2) in the KKA^y mouse model of human type-II diabetes for their ability to serve as insulin-sensitizing antihyperglycemic agents. Ketone 10 has proven to be the most potent of these thiazolidinediones in this in vivo assay. When 6-10 were compared *in vitro* in the 3T3-L1 cell line to 2 for their ability to augment insulin-stimulated lipogenesis, 10 was again the most potent compound with 6, 7, and 9 roughly equivalent to 2 in prolipogenetic activity. These data suggest that metabolites 6, 7, and 9 are likely to contribute to the pharmacological activity of pioglitazone (2), as had been previously reported for the metabolites of ciglitazone,³⁷ provided that the metabolic profile of 2 in the mouse resembles that reported for the rat and dog.²³⁻²⁵ The *in vitro* and *in* vivo biological activities presented for ketone 10 suggest its potential as a pioglitazone antihyperglycemic congener with somewhat greater potency and the possibility of a simpler metabolic profile.

Experimental Section

All reagents were used as received unless otherwise stated. All reactions were performed under a blanket of nitrogen, in oven (150 °C)-dried glassware with rigid exclusion of moisture from all reagents and glassware unless otherwise mentioned. Melting points were determined on a Mettler FP62 melting point apparatus and are uncorrected. Proton magnetic resonance spectra (¹H-NMR) were recorded on a Bruker AM-300 instrument at 300 MHz in deuteriochloroform unless otherwise indicated. Chemical shifts are reported in parts per million (δ scale) from internal tetramethylsilane. Data are reported as follows: chemical shifts (multiplicity (s = singlet, brs = broad singlet, dd = doublet of doublets, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (Hz), integration). ¹³C-NMR spectra were recorded on a Bruker AM-300 instrument at 75.4 MHz as solutions in deuteriochloroform unless otherwise indicated. Thin layer chromatography (TLC) was performed on E. Merck silica gel GF254 plates. Spots were made visible with UV light and/or exposure to I₂ vapors and/or dipping into a solution of ammonium molybdate (75 g) and ceric sulfate (2.5 g) in water and concentrated sulfuric acid (500 mL; 9:1, v/v) followed by heating. Flash column chromatography was performed according to the procedure of Still et al.³⁸ and eluted with the solvents specified.

Biological Procedures. (1) In Vivo Antihyperglycemic Activity. Obese, hyperglycemic, insulin resistant male KKA^y mice, 10-12 weeks of age, were obtained from the Upjohn colony and used as a model for insulin resistant diabetes (type-II).^{18,34} These mice are a cross between glucose intolerant black KK female mice and obese yellow male A^y mice. The yellow offspring KKA^y mice are obese, hyperglycemic, and insulin resistant at 10-12 weeks of age.35 KKAy mice were housed individually in shoebox cages and provided food (powdered laboratory chow) and water ad libitum. Animals were grouped into treatment and control groups (n = 6)through pretest blood glucose measurements, by bleeding from the retroorbital sinus with glucose levels measured with an Alpkem glucose autoanalyzer.35 Treatment groups had the selected compound administered as a food admixture at 100 mg/kg for 4 days. Weights of the animals were measured and recorded on day 1 and at 0730 h on day 5. At 0800 h on day 5 from the start of treatment, animals were bled from the retroorbital sinus and glucose levels were measured. The glucose level for the treated group (T) over the control group (C) was utilized to determine the antihyperglycemic activity of the test compounds. Pioglitazone (2) was dosed at 100 mg/ kg as the positive control, and results are reported as a T/C value.

(2) In Vitro Enhancement of Insulin-Regulated Differentiation of 3T3-L1 Cells to Adipocytes. The 3T3-L1 cell line, in the presence of the appropriate hormonal signals, undergoes differentiation from a fibroblastic adipoblast to a mature adipocyte capable of carrying out insulin-regulated lipogenesis.¹⁵ Pioglitazone (2) has been reported to markedly enhance the insulin-regulated differentiation of 3T3-L1 adipocytes.¹⁵ The 3T3-L1 cell line was from the American Type Culture Collection. Cells were maintained in Dubelco's modified Eagle's medium containing 5% fetal calf serum and 10 μ g/mL gentamicin. Cells were staged to differentiate by incubation for 48 h in medium containing 1 μ M dexamethasone and 0.5 mM 3-isobutyl-1-methylxanthine. Confluent cells were then incubated in Dubelco's modified Eagle's medium containing 5% fetal calf serum with insulin (150 nM) with and without added thiazolidinedione (0–10 μ M) for 48 h. Cells were then incubated with [14C]acetate for 1 h, and lipid was extracted into 2-propanol.¹⁵ [¹⁴C]Acetate incorporated into 2-propanol extractable material was quantitated by liquid scintillation counting.

3-Acetyl-6-methylpyridine (11). To a mechanically stirred suspension of sodium hydride (32.7 g of a 60%, w/w, oil dispersion, 818 mmol) in toluene (400 mL) and *N*,*N*-dimethylformamide (41 mL) was added approximately 10% of a

solution of methyl 5-methyl-nicotinate (61.8 g, 408 mmol) in ethyl acetate (85 mL), and the mixture was heated at 80 °C for 30 min. The remainder of the solution was added slowly over 2 h while maintaining an internal temperature of approximately 80 °C. After cooling to room temperature, the reaction mixture was diluted with water (1 L) and thoroughly extracted with ethyl acetate $(3 \times 1 L)$ and methylene chloride $(2 \times 1 \text{ L})$. The combined organic extracts were evaporated *in* vacuo, and the residue was heated under reflux in 10% (v/v) sulfuric acid (300 mL) for 2 h. After cooling to 0 °C, the reaction mixture was neutralized with solid K₂CO₃ and extracted with ethyl acetate (1.5 L). The organic extract was dried (Na₂SO₄), filtered, and evaporated in vacuo to give the crude ketone as a red-orange viscous liquid. The crude product was purified by distillation under reduced pressure to give 33.3 g (60%) of the desired methyl ketone 11 as a clear, pale yellow, viscous liquid: bp 58-60 °C (0.01 mmHg); TLC (Merck; acetone– \dot{CH}_2Cl_2 , 1:9, UV(+)) $R_f = 0.31$; ¹H-NMR (CDCl₃) δ 9.05 (d, J = 2.2 Hz, 1), 8.13 (dd, J = 8.1, 2.2 Hz, 1), 7.27 (d, J = 8.1 Hz, 1), 2.64 (s, 3), 2.62 (s, 3).

3-(1-Hydroxyethyl)-6-methylpyridine (12). To a stirring solution of ketone 11 (23.7 g, 175 mmol) in absolute EtOH (200 mL) at 0 $^\circ C$ was added NaBH4 (3.32 g, 87.7 mmol) portionwise over 1 h. The reaction mixture was stirred at 0 °C for 1.5 h before warming to room temperature. The mixture was partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic phase was dried (Na₂SO₄), filtered, and evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 450 g, 70 mm o.d., acetone-CH₂Cl₂, 1:3, 250 mL fractions), using the flash technique. Fractions 7-43 afforded 21.5 g (90%) of the target alcohol 12 as a clear, colorless oil: TLC (Merck; acetone-CH2-Cl₂, 1:3, UV(+)) $R_f = 0.18$; ¹H-NMR (CDCl₃) δ 8.30 (d, J = 2.2Hz, 1), 7.63 (dd, J = 8.0, 2.3 Hz, 1), 7.11 (d, J = 8.0 Hz, 1), 4.87 (q, J = 6.5 Hz, 1), 4.01 (brs, 1), 2.48 (s, 3), 1.48 (d, J = 6.5Hz. 3)

3-(1-(Methoxymethoxy)ethyl)-6-methylpyridine (13). A 60% (w/w) oil dispersion of NaH (3.35 g, 83.8 mmol) was washed with hexanes (3 \times 10 mL) and suspended in DMF (40 mL). The suspension was cooled to 0 °C, and a solution of alcohol 12 (9.58 g, 69.8 mmol) in DMF (50 mL) was added over 1 h. The reaction mixture was stirred at 0 °C for 1.5 h and cooled to -78 °C, and chloromethyl methyl ether (6.4 mL, 83.8 mmol) was added over 15 min. After the mixture warmed to room temperature, the reaction was carefully quenched by the careful addition of H₂O. Then the mixture was partitioned between EtOAc (150 mL) and H₂O (150 mL). The aqueous phase was extracted with two additional portions of EtOAc (150 mL), and the combined organic extracts were washed with H_2O (3 \times 150 mL) and brine, dried (Na₂SO₄), filtered, and evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 400 g, 70 mm o.d., acetone-CH₂Cl₂, 1:3, 250 mL fractions), using the flash technique. Fractions 4-9 were combined and evaporated in vacuo to give 10.05 g (79%) of the target compound 13 as a yellow oil: TLC (Merck; acetone-CH₂Cl₂, 1:9, UV(+)) $R_f = 0.33$; ¹H-NMR (CDCl₃) δ 8.46 (d, J = 2.1 Hz, 1), 7.60 (dd, J = 8.0, 2.3 Hz, 1), 7.16 (d, J = 8.0 Hz, 1), 4.77 (q, J = 6.6 Hz, 1), 4.57 (ABq, J = 20.8, 6.8 Hz, 2), 3.36 (s, 3), 2.57 (s, 3), 1.49 (d, J = 6.6 Hz, 3); IR (neat) 3408, 2976, 2889, 2823, 1603, 1571, 1492, 1450, 1404, 1374, 1220, 1156, 1106, 1039, 1025, 1001, 919, 861, 835, 739, 644 cm⁻¹; EI/MS (70 eV) 181 (M⁺, 3.2), 166 (33.7), 149 (13.4), 136 (5.5), 120 (53.8), 45 (base); HRMS (EI) calcd for C₁₀H₁₅NO₂ (M⁺) 181.1103, found 181.1101.

2-(5-(1-(Methoxymethoxy)ethyl)-2-pyridyl)ethanol (14). A stirring solution of the methylpyridine **13** (5.38 g, 29.7 mmol) and 37% aqueous formaldehyde (2.41 g, 29.7 mmol) was heated at 160 °C in a sealed glass tube for 5 h. After cooling to room temperature, the solvent was evaporated *in vacuo*. Residual H₂O was removed by azeotropic distillation of toluene (2×). The crude product was purified by chromatography on a column of silica gel (230–400 mesh, 400 g, 70 mm o.d., packed and eluted with acetone–CH₂Cl₂, 25:75 (3 L), then MeOH– acetone–CH₂Cl₂, 2.5:25:72.5, 250 mL fractions), using the flash technique. Fractions 5–9 afforded 3.06 g (57%) of recovered starting methylpyridine **13**. Fractions 19–27 afforded 1.71 g

Metabolites of the Antidiabetic Agent Pioglitazone

(27%) of the target (hydroxyethyl)pyridine **14** as a yellow oil: TLC (Merck; acetone–CH₂Cl₂, 25:75, UV(+)) $R_f = 0.23$; ¹H-NMR (CDCl₃) δ 8.46 (d, J = 2.1 Hz, 1), 7.66 (dd, J = 8.0, 2.3 Hz, 1), 7.20 (d, J = 8.0 Hz, 1), 4.79 (q, J = 6.6 Hz, 1), 4.5b (ABq, J = 23.6, 6.8 Hz, 2), 4.02 (t, J = 5.6 Hz, 2), 3.36 (s, 3), 3.04 (t, J = 5.6 Hz, 2), 1.49 (d, J = 6.6 Hz, 3); IR (neat) 3374, 2974, 2948, 2933, 1603, 1571, 1491, 1444, 1374, 1217, 1155, 1136, 1100, 1060, 1037, 998, 919, 850, 837 cm⁻¹; EI/MS (70 eV) 211 (M⁺, 34.1), 194 (90.7), 181 (39.4), 166 (7.4), 150 (27), 134 (25.7), 120 (74), 45 (base); HRMS (EI) calcd for C₁₁H₁₇-NO₃ (M⁺) 211.1208, found 211.1213.

4-(2-(5-(1-(Methoxymethoxy)ethyl)-2-pyridyl)ethoxy)benzaldehyde (15). To a stirring solution of the (hydroxyethyl)pyridine 14 (4.06 g, 19.2 mmol), p-hydroxybenzaldehyde (2.35 g, 19.2 mmol), and triphenylphosphine (5.54 g, 21.1 mmol) in THF (100 mL) at 0 °C was added diethyl azodicarboxylate (3.3 mL, 21.1 mmol) over 15 min. After stirring at room temperature for 18 h, the solvent was evaporated in vacuo. The resulting yellow oil was chromatographed on a column of silica gel (230-400 mesh, 300 g, 70 mm o.d., packed with acetone-CH₂Cl₂, 25:75, eluted with acetone-CH₂Cl₂, 35: 65, 250 mL fractions), using the flash technique. Fractions 3-6 afforded an oily solid which consisted of the target compound 15 as a mixture with dicarbethoxyhydrazine. This material was treated with Et₂O-hexanes, 50:50, and the white solid (dicarbethoxyhydrazine) was removed by suction filtration. The mother liquor was evaporated in vacuo, and the residue was purified by chromatography on a column of silica gel (230-400 mesh, 500 g, 70 mm o.d., EtOAc-hexanes, 40: 60, 250 mL fractions), using the flash technique. Fractions 13-30 were combined and evaporated in vacuo to give 3.75 g (62%) of the target compound 15 as a yellow oil: TLC (Merck; acetone – CH₂Cl₂, 10:90, UV(+)) $R_f = 0.42$; ¹H-NMR (CDCl₃) δ 9.87 (s, 1), 8.52 (d, J = 2.1 Hz, 1), 7.80 (m, 2), 7.64 (dd, J =8.0, 2.3 Hz, 1), 7.28 (s, 1), 7.01 (d, J = 8.7 Hz, 2), 4.79 (q, J = 6.6 Hz, 1), 4.58 (ABq, J = 6.8 Hz, 2), 4.46 (t, J = 6.7 Hz, 2), 3.36 (s, 3), 3.30 (t, J = 6.6 Hz, 2), 1.49 (d, J = 6.6 Hz, 3); IR (Nujol) 2933, 2887, 2838, 2824, 1695, 1601, 1578, 1510, 1259, 1216, 1160, 1100, 1036, 1024 cm⁻¹; EI/MS (70 eV) 315 (M⁺) 4.7), 284 (2.1), 270 (1.3), 254 (10.6), 224 (10.8), 210 (7.3), 194 (74.7), 181 (base); HRMS (EI) calcd for C₁₈H₂₁NO₄ (M⁺) 315.1470, found 315.1479.

5-(4-(2-(5-(1-(Methoxymethoxy)ethyl)-2-pyridyl)ethoxy)benzylidene)-2,4-thiazolidinedione (16). A stirring solution of aldehyde 15 (3.67 g, 11.6 mmol), 2,4-thiazolidinedione (1.36 g, 11.6 mmol), and piperidine (0.50 g, 5.82 mmol) in absolute EtOH (25 mL) was heated under reflux for 18 h. After cooling to room temperature, the solvent was evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 500 g, 70 mm o.d., packed with acetone-CH₂Cl₂, 10:90, eluted with acetone-CH₂-Cl₂, 10:90 (3 L), 20% acetone-CH₂Cl₂, 20:80 (2 L), and MeOHacetone-CH₂Cl₂, 2.5:25:72.5, 250 mL fractions) using the flash technique. Fractions 17-23 afforded 2.77 g (58%) of the target compound 16 as a yellow solid (mp 122-123 °C): TLC (Merck; acetone – CH₂Cl₂, 10:90, UV(+)) $\hat{R}_{f} = 0.30$; ¹H-NMR (CDCl₃) δ 8.52 (d, J = 2.1 Hz, 1), 7.72 (dd, J = 8.0, 2.2 Hz, 1), 7.64 (s, 1), 7.39 (d, J = 8.8 Hz, 2), 7.32 (d, J = 8.0 Hz, 1), 6.96 (d, J = 8.8Hz, 2), 4.81 (q, J = 6.5 Hz, 1), 4.59 (ABq, J = 6.8 Hz, 2), 4.48 (t, J = 6.2 Hz, 2), 3.37 (s, 3), 3.35 (t, J = 6.2 Hz, 2), 1.51 (d, J = 6.5 Hz, 3); IR (Nujol) 1730, 1696, 1597, 1508, 1291, 1272, 1240, 1229, 1184, 1109, 1056, 1046, 1033, 1017 cm⁻¹; EI/MS (70 eV) 414 (M⁺, 11.0), 353 (5.9), 221 (47.9), 194 (68.2), 181 (33.9), 178 (34.6), 150 (base). Anal. (C₂₁H₂₂N₂O₅S) C, H, N.

5-(4-(2-(5-(1-(Methoxymethoxy)ethyl)-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione (17). To a stirring solution of CoCl₂•6H₂O (10 mg, 0.04 mmol) and 2,2'-dipyridyl (24.7 mg, 0.158 mmol) in H₂O (10 mL) was added 1.0 N NaOH (0.13 mL) followed by NaBH₄ (568 mg, 15.0 mmol), and the resulting deep blue mixture was cooled to 0 °C. A solution of the olefin **16** (1.85 g, 4.46 mmol) in DMF (15 mL) was added over 0.5 h. The reaction mixture stirred for 18 h at room temperature, and then an additional portion of NaBH₄ (250 mg) was added. After stirring for 24 h, acetic acid was added until the pH of the mixture was approximately 6. The mixture was diluted with H₂O (25 mL) and extracted with CH₂Cl₂ (2 × 50 mL). The combined organic extracts were washed with brine, dried (Na₂SO₄), filtered, and evaporated in vacuo. The crude product was dissolved in hot acetone/CH2Cl2 and purified by chromatography on a column of silica gel (230-400 mesh, 300 g, 70 mesh)mm o.d., acetone-CH₂Cl₂, 25:75, 250 mL fractions), using the flash technique. Fractions 5-9 afforded 1.13 g (61%) of the target compound **17** as an off-white solid (mp 130-132 °C): TLC (Merck; acetone-CH₂Cl₂, 10:90, UV(+)) $R_f = 0.17$; ¹H-NMR (CDCl₃) δ 8.51 (d, J = 2.2 Hz, 1), 7.64 (d, J = 6.0 Hz, 1), 7.28 (d, J = 8.0 Hz, 1), 7.12 (d, J = 8.6 Hz, 2), 6.83 (d, J = 8.6Hz, 2), 4.79 (q, J = 6.5 Hz, 1), 4.58 (ABq, J = 6.8 Hz, 2), 4.46 (dd, J = 9.3, 3.9 Hz, 1), 4.32 (t, J = 6.4 Hz, 2), 3.42 (dd, J =14.1, 3.9 Hz, 1), 3.36 (s, 3), 3.27 (t, J = 6.4 Hz, 2), 3.09 (dd, J= 14.1, 9.3 Hz, 1), 1.49 (d, J = 6.5, 3); IR (Nujol) 1705, 1514, 1252, 1165, 1152, 1058, 1034, 1022 cm⁻¹; EI/MS (70 eV) 416 (M⁺, 2.3), 355 (8.4), 346 (2.1), 194 (92.1), 181 (base). Anal. (C₂₁H₂₄N₂O₅S) C, H, N.

5-(4-(2-(5-(1-Hydroxyethyl)-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione (6). To a stirring suspension of 17 (0.50 g, 1.20 mmol) in MeOH (20 mL) was added 2 N aqueous HCl (1.5 mL), and the resulting solution was heated under reflux for 2 h. After cooling to room temperature, the reaction mixture was evaporated *in vacuo*. The residue was dissolved in H₂O (25 mL), and the solution was neutralized with saturated aqueous NaHCO₃. The resulting white precipitate was collected by filtration, washed with H₂O, and dried. The crude product was purified by chromatography on a small column of silica gel (acetone-CH2Cl2-MeOH) to afford 0.43 g (98%) of 6 as an off-white solid (mp 153-158 °C): TLC (Merck; MeOH-CH₂Cl₂, 5:95, UV(+)) $R_f = 0.15$; ¹H-NMR (CDCl₃) δ 8.49 (d, J = 2.1 Hz, 1), 7.70 (dd, J = 8.0, 2.3 Hz, 1), 7.33 (d, J= 8.0 Hz, 1), 7.16 (d, J = 8.6 Hz, 2), 6.89 (d, J = 8.6 Hz, 2), 4.86 (dd, J = 9.0 Hz, 4.3, 1), 4.78 (q, J = 6.5, 1), 4.33 (t, J =6.6 Hz, 2), 3.42 (brs, 1), 3.32 (dd, J = 14.1, 4.3 Hz, 1), 3.17 (dd, J = 8.1, 6.6 Hz, 2), 3.06 (dd, J = 14.1, 9.0 Hz, 1), 1.36 (d, J = 6.5, 3); IR (Nujol) 1611, 1515, 1473, 1333, 1318, 1253, 1162, 1023 cm⁻¹; EI/MS (70 eV) 372 (M⁺, 11.8), 193 (7.7), 166 (5.1), 150 (base); HRMS (EI) calcd for $C_{19}H_{20}N_2O_4S$ (M⁺) 372.1144, found 372.1139.

3-(2-Methyl-1,3-dioxolan-2-yl)-6-methylpyridine (18). To a stirring mixture of the methylacetylpyridine **11** (14.4 g, 106 mmol) in toluene (100 mL) were added ethylene glycol (8.9 mL, 160 mmol) and p-toluenesulfonic acid monohydrate (22.3 g, 117 mmol). The mixture was heated under reflux for 8 h, and H₂O was removed from the system through the use of a Dean-Stark trap. After cooling to room temperature, the reaction mixture was neutralized with K₂CO₃. The mixture was diluted with H₂O (100 mL) and extracted with EtOAc (150 mL). The organic extract was washed with H₂O and brine (150 mL each), dried (Na₂SO₄), filtered, and evaporated in vacuo to give the desired ketal 6 as a light yellow oil. Distillation afforded 17.4 g (92%) of 18 as a clear, colorless, viscous liquid (bp 67–68 °C, 0.06 mmHg): TLC (Merck; acetone–CH₂Cl₂, 10: 90, UV(+)) $R_f = 0.29$; ¹H-NMR (CDCl₃) δ 8.61 (d, J = 2.1 Hz, 1), 7.66 (dd, J = 8.0, 2.3 Hz, 1), 7.13 (d, J = 8.0 Hz, 1), 4.06 (m, 2), 3.78 (m, 2), 2.56 (s, 3), 1.66 (s, 3); IR (Nujol) 3401, 3063, 3040, 1603, 1488, 1376, 1261, 1223, 1200, 1108, 1088, 1041, 1023, 949, 891, 873, 835, 738 cm⁻¹; EI/MS (70 eV) 164 (base), 120 (47.6), 87 (35.5), 42 (34.6). Anal. (C10H13NO2) C, H, N.

2-(5-(2-Methyl-1,3-dioxolan-2-yl)-2-pyridyl)ethanol (19). A stirring solution of the ketal 18 (40.0 g, 223 mmol) and 37% aqueous formaldehyde (18.1 g, 223 mmol) was heated at 150 °C in a sealed glass tube for 5 h. After cooling to room temperature, the solvent was evaporated in vacuo, and residual H₂O was removed by azeotropic distillation with toluene $(2 \times 100 \text{ mL})$. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 500 g, 70 mm o.d., packed and eluted with acetone-CH₂Cl₂, 25:75 (3 L), then MeOH-acetone-CH2Cl2, 2.5:25:72.5, 250 mL fractions), using the flash technique. Fractions 5-9 afforded 24.91 g (62%) of recovered starting material 18. Fractions 12-30 afforded 11.36 g (24%) of the target (hydroxyethyl)pyridine 19 as a yellow oil: TLC (Merck; acetone $-CH_2Cl_2$, 25:75, UV(+)) $R_f =$ 0.23; ¹H-NMR (CDCl₃) δ 8.62 (d, J = 2.2 Hz, 1), 7.74 (dd, J =8.0, 2.3 Hz, 1), 7.17 (d, J = 8.0 Hz, 1), 4.05 (m, 4), 3.81 (m, 2), 3.03 (t, J = 5.5 Hz, 2), 1.66 (s, 3); IR (Nujol) 1600, 1567, 1488,

1448, 1260, 1203, 1103, 1092, 1052, 1044, 1029, 951, 868 cm $^{-1};$ EI/MS (70 eV) 209 (M $^+,$ 60.7), 194 (46.5), 192 (base), 179 (48.8), 164 (72.2). Anal. (C $_{11}H_{15}NO_3$) C, H, N.

4-(2-(5-(2-Methyl-1,3-dioxolan-2-yl)-2-pyridyl)ethoxy)benzaldehyde (20). To a stirring solution of the (hydroxyethyl)pyridine 19 (3.58 g, 17.1 mmol), p-hydroxybenzaldehyde (2.30 g, 18.8 mmol), and triphenylphosphine (4.94 g, 18.8 mmol) in THF (75 mL) at 0 °C was added a solution of diethyl azodicarboxylate (3.0 mL, 18.8 mmol) in THF (10 mL) over a period of 0.5 h. After stirring at room temperature for 18 h, the solvent was evaporated in vacuo. The resulting yellow oil was purified by chromatography on a column of silica gel (230-400 mesh, 200 g, 70 mm o.d., packed with acetone-CH₂Cl₂, 1:3, eluted with acetone-CH₂Cl₂, 35:65, 250 mL fractions), using the flash technique. Fractions 3-6 afforded an oily solid which consisted of the target compound 20 as a mixture with dicarbethoxyhydrazine. This material was treated with Et₂Ohexanes (1:1, 100 mL), and the white solid (dicarbethoxyhydrazine) was removed by filtration. The solvent was evaporated in vacuo, and the residue was purified by chromatography on a column of silica gel (230-400 mesh, 500 g, 70 mm o.d., EtOAc-hexanes, 2:3, 250 mL fractions), using the flash technique. Fractions 13-30 were combined and evaporated in vacuo to give 2.98 g (55%) of 20 as a pale yellow oil: TLC (Merck; acetone-CH₂Cl₂, 10:90, UV(+)) $R_f = 0.35$; ¹H-NMR (CDCl₃) δ 9.87 (s, 1), 8.67 (d, J = 2.2 Hz, 1), 7.82 (m, 2), 7.73 (dd, J = 7.9, 2.3 Hz, 1), 7.25 (d, J = 9.3 Hz, 1), 7.01 (m, 2), 4.46 (t, J = 6.6 Hz, 2), 4.07 (m, 2), 3.76 (m, 2), 3.30 (t, J = 6.6Hz, 2), 1.67 (s, 3); IR (Nujol) 1694, 1600, 1578, 1510, 1259, 1216, 1200, 1161, 1039, 1022, 834 cm⁻¹; EI/MS (70 eV) 313 (M⁺, 14.1), 298 (10.6), 192 (82.6), 179 (base). Anal. (C₁₈H₁₉-NO₄) C, H, N.

5-(4-(2-(5-(2-Methyl-1,3-dioxolan-2-yl)-2-pyridyl)ethoxy)benzylidene)-2,4-thiazolidinedione (21). A stirring solution of the aldehyde 20 (3.60 g, 11.5 mmol), 2,4-thiazolidinedione (1.35 g, 11.5 mmol), and piperidine (0.49 g, 5.74 mmol) in absolute EtOH (100 mL) was heated under reflux for 18 h. Upon cooling to room temperature, a precipitate formed. The mixture was cooled to 0 °C, and the solid was collected by filtration, washed with Et₂O, and dried in vacuo to afford 2.67 g (56%) of **21** as a light yellow solid (mp 163-164 °C): TLC (Merck; acetone- CH_2Cl_2 , 10:90, UV(+)) $R_f = 0.22$; ¹H-NMR (DMSO- d_6) δ 8.35 (d, J = 2.2 Hz, 1), 7.53 (m, 2), 7.33 (d, J =8.8 Hz, 2), 7.16 (dd, J = 8.1 Hz, 1), 6.89 (d, J = 8.8 Hz, 2), 4.24 (t, J = 6.5 Hz, 2), 3.79 (m, 2), 3.51 (m, 2), 3.15 (brs, 1), 3.00 (t, J = 6.5 Hz, 2), 1.37 (s, 3); IR (Nujol) 1731, 1696, 1596, 1509, 1289, 1271, 1235, 1184, 1165, 1055, 1039, 1031, 1017, 824 cm⁻¹; EI/MS (70 eV) 412 (M⁺, 15.0), 221 (4.2), 192 (base). Anal. (C₂₁H₂₀N₂O₅S) C, H, N.

5-(4-(2-(5-(2-Methyl-1,3-dioxolan-2-yl)-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione (22). To a stirring solution of CoCl₂·6H₂O (7.45 mg, 0.025 mmol) and dimethylglyoxime (116 mg, 1.00 mmol) in H₂O (40 mL) was added 1.0 N NaOH (4 drops) followed by NaBH₄ (568 mg, 15.0 mmol), and the resulting deep blue mixture was cooled to 0 °C. A solution of the olefin 21 (2.06 g, 5.00 mmol) in THF-DMF (2:1, 30 mL) was added over 0.5 h. The reaction mixture was allowed to slowly warm to room temperature and stirred for 18 h. Acetic acid was added until the pH of the mixture was approximately 6. The mixture was then diluted with H_2O (25 mL) and extracted with CH_2Cl_2 (2 \times 50 mL). The combined extracts were washed with brine, dried (Na₂SO₄), filtered, and evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 300 g, 70 mm o.d., packed with acetone-CH₂Cl₂, 10:90, eluted with acetone-CH₂Cl₂, 15:85, 220 mL fractions), using the flash technique. Fractions 8-12 afforded 1.99 g (96%) of the target compound 22 as a white solid (mp 59-61 °C): TLC (Merck; acetone-CH₂Cl₂, 10:90, UV(+)) $R_f = 0.30$; ¹H-NMR (CDCl₃) δ 8.67 (d, J = 2.1 Hz, 1), 7.73 (dd, J = 8.0, 2.2 Hz, 1), 7.26 (d, J = 8.0 Hz, 1), 7.13 (d, J = 8.6 Hz, 2), 6.84 (d, J = 8.6 Hz, 2), 4.47 (dd, J = 9.3, 3.9 Hz, 1), 4.32 (t, J = 6.4 Hz, 2), 4.07 (m, 2), 3.79 (m, 2), 3.42 (dd, J = 14.1, 3.8 Hz, 1), 3.27 (t, J = 6.4Hz, 2), 3.10 (ABq, J = 14.1, 9.3 Hz, 1), 1.66 (s, 3); IR (Nujol) 1752, 1698, 1611, 1512, 1247, 1039, 1032 cm⁻¹; EI/MS (70 eV) 414 (M⁺, 1.9), 399 (1.6), 344 (1.7), 223 (2.8), 192 (base); HRMS (EI) calcd for $C_{21}H_{22}N_2O_5S$ (M⁺) 414.1249, found 414.1258.

5-(4-(2-(5-(1-Oxoethyl)-2-pyridyl)ethoxy)benzyl)-2,4thiazolidinedione (7). To a stirring solution of 22 (2.72 g, 6.56 mmol) in THF (50 mL) was added 4 N HCl (50 mL), and the solution was stirred at room temperature for 18 h. The reaction mixture was neutralized with saturated aqueous NaHCO₃ (pH \approx 7) and extracted with CH₂Cl₂ (2 \times 50 mL). The combined extracts were washed with H₂O (50 mL) and brine (50 mL), dried (Na₂SO₄), filtered, and evaporated in vacuo to afford a pale yellow oil. Trituration with CH_2Cl_2 gave 2.38 g (98%) of 7 as a white solid which was recrystallized from EtOAc-hexanes (mp 106-107 °C); TLC (Merck; acetone- CH_2Cl_2 , 10:90, UV(+)) $R_f = 0.13$; ¹H-NMR (CDCl₃) δ 9.65 (brs, 1), 9.11 (d, J = 1.9 Hz, 1), 8.19 (dd, J = 8.1, 2.3 Hz, 1), 7.41 (d, J = 8.1 Hz, 1), 7.12 (d, J = 8.6 Hz, 2), 6.82 (d, J = 8.6 Hz, 2), 4.48 (dd, J = 9.3, 3.9 Hz, 1), 4.36 (t, J = 6.2 Hz, 2), 3.42 (dd, J = 14.1, 3.9 Hz, 1), 3.34 (t, J = 6.2 Hz, 2), 3.10 (dd, J = 14.1, 9.3 Hz. 1). 2.63 (s. 3): IR (Nuiol) 1703. 1612. 1600. 1514. 1333. 1316, 1276, 1250, 1181, 1159, 1032, 1024 cm⁻¹; EI/MS (70 eV) 370 (M+, 2.3), 254 (4.5), 223 (5.1), 148 (base); HRMS (EI) calcd for C₁₉H₁₈N₂O₄S (M⁺) 370.0987, found 370.0992.

(6-Methyl-3-pyridyl)methanol (23). To a stirring suspension of lithium aluminum hydride (3.80 g, 100 mmol) in dry THF (100 mL) at 10 °C was added a solution of methyl 5-methylnicotinate (30.23 g, 200 mmol) in THF (125 mL) over 1.5 h. After the mixture stirred at 0 °C for 30 min, the reaction was carefully quenched by the slow addition of H₂O (25 mL). The reaction mixture was filtered through a pad of Celite, and the pad was thoroughly rinsed with Et₂O. The solution was dried (Na₂SO₄), filtered, and evaporated in vacuo. The resulting crude alcohol was purified by distillation under reduced pressure (bp 98-100 °C, 0.65 mmHg) to furnish 18.74 g (73%) of the known alcohol²⁶ 23 as a clear liquid which crystallized upon cooling (mp 37-39 °C): TLC (Merck; MeOH-CH₂Cl₂, 1.9, UV(+)) $R_f = 0.32$; ¹H-NMR (CDCl₃) δ 8.30 (d, J = 2.03Hz, 1), 7.60 (dd, J = 7.93, 2.23 Hz, 1), 7.12 (d, J = 7.94 Hz, 1), 4.87 (brs, 1), 4.63 (s, 2), 2.49 (s, 3).

3-((Methoxymethoxy)methyl)-6-methylpyridine (24). NaH (4.80 g of a 60% oil dispersion, 120 mmol) was washed with three portions of hexanes and suspended in DMF (25 mL). To the mechanically stirred suspension at -10 °C was added a solution of alcohol 23 (12.32 g, 100 mmol) in DMF (50 mL) over 1 h. After stirring for 30 min, the reaction mixture was cooled to -15 °C, and MOMCl (9.1 mL, 120 mmol) was added over 30 min. After the mixture stirred for 30 min, the reaction was quenched by the careful addition of H₂O. The reaction mixture was allowed to warm to room temperature and partitioned between H₂O (150 mL) and EtOAc (150 mL). The organic phase was washed with three portions of H₂O (100 mL) and brine, dried (Na₂SO₄), filtered, and evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 400 g, 70 mm o.d., acetone-CH₂Cl₂, 20:80, 210 mL fractions). Fractions 5-16 were combined and evaporated in vacuo to afford 12.22 g (73%) of the target methoxy methyl ether 24 as a yellow oil: TLC (Merck; MeOH-CH₂Cl₂, 5:95, UV(+)) $R_f = 0.21$; ¹H-NMR (CDCl₃) δ 8.48 (d, J = 2.1 Hz, 1), 7.58 (dd, J = 7.9, 2.3 Hz, 1), 7.15 (d, J = 8.0 Hz, 1), 4.70 (s, 2), 4.57 (s, 2), 3.40 (s, 3), 2.55 (s, 3).

2-(5-((Methoxymethoxy)methyl)-2-pyridyl)ethanol (25). A stirring solution of the methylpyridine 24 (40.0 g, 223 mmol) and 37% aqueous formaldehyde (18.1 g, 223 mmol) was heated at 150 °C (preheated oil bath) in a sealed glass tube for 5 h. After cooling to room temperature, the solvent was evaporated in vacuo, and residual H₂O was removed by azeotropic distillation with toluene (2 \times 50 mL). The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 500 g, 70 mm o.d., packed and eluted with acetone-CH₂Cl₂, 25:75 (3 L), then MeOH–acetone–CH₂Cl₂, 2.5:25:72.5, 250 mL fractions), using the flash technique. Fractions 5-9 afforded 24.11 g (60%) of recovered 24. Fractions 12-30 afforded 13.72 g (29%) of the target (hydroxyethyl)pyridine 25 as a yellow oil: TLC (Merck; MeOH-CH₂Cl₂, 10:90, UV(+)) $R_f = 0.41$; ¹H-NMR (CDCl₃) δ 8.62 (d, J = 2.2 Hz, 1), 7.74 (dd, J = 8.0, 2.3 Hz, 1), 7.17 (d, J = 8.0 Hz, 1), 4.05 (m, 4), 3.81 (m,

Metabolites of the Antidiabetic Agent Pioglitazone

2), 3.03 (t, J = 5.5 Hz, 2), 1.66 (s, 3); IR (liquid) 3385, 3285, 2946, 2885, 1606, 1492, 1150, 1104, 1050, 1034, 920 cm⁻¹; EI/ MS (70 eV) 197 (M⁺, 16.5), 180 (42.5), 167 (21.1), 106 (39.4), 79 (base). Anal. (C₁₀H₁₅NO₃) C, H, N.

4-(2-(5-((Methoxymethoxy)methyl)-2-pyridyl)ethoxy)benzaldehyde (26). To a stirring solution of (hydroxyethyl)pyridine 25 (3.58 g, 17.1 mmol), p-hydroxybenzaldehyde (2.30 g, 18.8 mmol), and triphenylphosphine (4.94 g, 18.8 mmol) in THF (75 mL) at 0 $^\circ\rm C$ was added a solution of diethyl azodicarboxylate (3.0 mL, 18.8 mmol) in THF (10 mL) over 15 min. After stirring at room temperature for 18 h, the solvent was evaporated in vacuo to furnish a yellow oil which was purified by chromatography on a column of silica gel (230-400 mesh, 200 g, 70 mm o.d., packed with acetone-CH2Cl2, 25:75, eluted with acetone-CH₂Cl₂, 35:65, 250 mL fractions), using the flash technique. Fractions 3-6 afforded an oily solid which consisted of the target compound 26 admixed with dicarbethoxyhydrazine. This material was treated with Et₂Ohexanes (1:1), and the white solid (dicarbethoxyhydrazine) was removed by filtration. The mother liquor was evaporated in vacuo, and the residue was purified by chromatography on a column of silica gel (230-400 mesh, 500 g, 70 mm o.d., EtOAchexanes, 2:3, 250 mL fractions), using the flash technique. Fractions 13-30 were combined and evaporated in vacuo to give 3.14 g (58%) of the target compound 26 as a clear, yellow oil: TLC (Merck; EtOAc-hexanes, 50:50, UV(+)) $R_f = 0.20$; ¹H-NMR (CDCl₃) δ 9.87 (s, 1), 8.67 (d, J = 2.2 Hz, 1), 7.82 (m 1), 7.73 (dd, J = 7.9, 2.3 Hz, 1), 7.25 (d, J = 9.3 Hz, 1), 7.01 (m, 2), 4.46 (t, J = 6.6 Hz, 2), 4.07 (m, 2), 3.76 (m, 2), 3.30 (t, J = 6.6 Hz, 2), 1.67 (s, 3); IR (Nujol) 1701, 1687, 1605, 1602, 1580, 1512, 1263, 1252, 1216, 1169, 1148, 1117, 1057, 1028, 1022, 837 cm⁻¹; EI/MS (70 eV) 301 (M⁺, 3.6), 240 (2.6), 196 (9.8), 180 (71.7), 167 (base). Anal. (C₁₇H₁₉NO₄) C, H, N,

4-(2-(5-(Hydroxymethyl)-2-pyridyl)ethoxy)benzaldehyde (27). To a stirring solution of the MOM ether 26 (1.51 g, 5.00 mmol) in MeOH (5 mL) was added 2 N aqueous HCl (5 mL). The solution was heated under reflux for 2 h and then allowed to cool to room temperature, and the solvent was evaporated in vacuo. The residue was neutralized with saturated aqueous NaHCO₃ and then extracted with two portions (25 mL) of EtOAc. The combined extracts were washed with brine (25 mL), dried (Na₂SO₄), filtered, and evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 300 g, 70 mm o.d., packed and eluted with acetone-CH₂Cl₂, 20: 80) using the flash technique. Fractions containing the desired alcohol 27 (as determined by TLC) were combined and evaporated in vacuo to afford 1.24 g (96%) of 27 as a white solid (mp 90-91 °C): TLC (Merck; MeOH-CH2Cl2, 5:95, UV-(+)) $R_f = 0.13$; ¹H-NMR (CDCl₃) δ 9.84 (s, 1), 8.46 (d, J = 1.90Hz, 1), 7.81 (dm, J = 8.76 Hz, 2), 7.68 (dd, J = 7.97, 2.20 Hz, 1), 7.26 (d, J = 7.97 Hz, 1), 6.97 (dm, J = 8.76 Hz, 2), 4.70 (s, 2), 4.41 (t, J = 6.53 Hz, 2), 3.47 (brs, 1), 3.26 (t, J = 6.53 Hz, 2); IR (Nujol) 3229, 1696, 1689, 1603, 1510, 1463, 1310, 1259, 1158, 1024, 825 cm⁻¹; EI/MS (70 eV) 257 (M⁺, 3.8), 136 (base), 123 (97.1). Anal. (C15H15NO3) C, H, N.

4-(2-(5-(Cyanomethyl)-2-pyridyl)ethoxy)benzaldehyde (28). To a stirring solution of the alcohol 27 (3.86 g, 15.0 mmol) in CHCl₃ (100 mL) was added SOCl₂ (11 mL, 150 mmol), and the solution was heated under reflux for 1 h. After cooling to room temperature, H₂O (100 mL) and CHCl₃ (100 mL) were added, and the mixture was neutralized with saturated aqueous NaHCO₃. The aqueous phase was separated and extracted with CHCl₃ (100 mL). The combined organic phases were washed with brine (200 mL), dried (Na₂- SO_4), filtered, and evaporated *in vacuo*. The resulting yellow oil was dissolved in DMF (75 mL), and KCN (1.47 g, 22.5 mmol) was added in one portion. The resulting reddish-brown mixture was stirred at room temperature for 16 h. The mixture was cast into H₂O (500 mL) and extracted with three portions of EtOAc (1 L total volume). The combined extracts were washed with H_2O (3 \times 500 mL) and brine, dried (Na₂-SO₄), filtered and evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 300 g, 70 mm o.d., packed with CH₂Cl₂, eluted with acetone-CH₂Cl₂, 10:90, 275 mL fractions), using the flash technique. Fractions 10–13 were combined and evaporated *in vacuo* to give 2.46 g (61%) of the target compound **28** as a yellow solid (mp 70–71 °C): TLC (Merck; acetone–CH₂Cl₂, 10:90, UV(+)) $R_f = 0.31$; ¹H-NMR (CDCl₃) δ 9.87 (s, 1), 8.52 (brd, J = 2.37 Hz, 1), 7.81 (dm, J = 6.76 Hz, 2), 7.67 (dd, J = 8.04, 2.37 Hz, 1), 7.33 (d, J = 8.04 Hz, 1), 6.99 (dm, J = 6.76 Hz, 2), 4.61 (t, J = 6.45 Hz, 2), 3.76 (s, 2), 3.31 (t, J = 6.45 Hz, 2); IR (Nujol) 3049, 3019, 2811, 1694, 1605, 1599, 1579, 1507, 1492, 1425, 1252, 1024, 833 cm⁻¹; EI/MS (70 eV) 266 (M⁺, 6.1), 145 (base), 132 (65.5). Anal. (C₁₉H₁₇N₃O₃S·0.045CH₂Cl₂) C, H, N.

5-(4-(2-(5-(Cvanomethyl)-2-pyridyl)ethoxy)benzylidene)-2,4-thiazolidinedione (29). A stirring solution of the aldehyde 28 (3.60 g, 11.5 mmol), 2,4-thiazolidinedione (1.35 g, 11.5 mmol), and piperidine (0.49 g, 5.74 mmol) in absolute EtOH (100 mL) was heated under reflux for 18 h. Upon cooling to room temperature, a precipitate formed. The mixture was cooled to 0 °C, and the solid was collected by filtration, washed with Et₂O, and dried to afford 3.10 g (65%) of the target compound **29** as a light yellow solid (mp 163-164 °C): TLC (Merck; acetone- CH_2Cl_2 , 10:90, UV(+)) $R_f = 0.24$; ¹H-NMR $(DMSO-d_6) \delta 8.49 (d, J = 2.2 Hz, 2), 7.75 (s, 1), 7.74 (dd, J =$ 7.9, 2.2 Hz, 1), 7.53 (d, J = 8.8 Hz, 2), 7.42 (d, J = 7.9 Hz, 1), 7.09 (d, J = 8.8 Hz, 2), 4.44 (t, J = 6.5 Hz, 2), 4.07 (s, 2), 3.22 (t, J = 6.5 Hz, 2); IR (Nujol) 1731, 1695, 1597, 1512, 1256, 1181, 1160, 1017, 692 cm⁻¹; EI/MS (70 eV) 365 (M⁺, 14.5), 221 (22.8), 150 (43.8), 145 (base). Anal. (C₁₉H₁₅N₃O₃S·0.28H₂O) C, H, N.

5-(4-(2-(5-(Cyanomethyl)-2-pyridyl)ethoxy)benzyl)-2,4thiazolidinedione (30). To a stirring solution of CoCl₂·6H₂O (8.4 mg, 0.028 mmol) and 2,2'-dipyridyl (176 mg, 1.12 mmol) in H₂O (40 mL) was added 1.0 N NaOH (4 drops) followed by NaBH₄ (568 mg, 15.0 mmol), and the resulting deep blue mixture was cooled to 0 °C. A solution of the olefin 29 (2.06 g, 5.00 mmol) in THF-DMF (2:1, 30 mL) was added over 0.5 h. The reaction mixture was allowed to slowly warm to room temperature and stirred for 18 h. Acetic acid was added until the pH of the mixture was ca. 6. The mixture was diluted with H_2O (25 mL) and extracted with two portions of CH_2Cl_2 $(2 \times 50 \text{ mL})$. The combined organic extracts were washed with brine (100 mL), dried (Na₂SO₄), filtered, and evaporated in vacuo. The crude product was purified by chromatography on a column of silica gel (230-400 mesh, 300 g, 70 mm o.d., packed with acetone-CH2Cl2, 10:90, eluted with acetone-CH2-Cl₂, 15:85, 220 mL fractions), using the flash technique. Fractions 8-12 afforded 1.03 g (56%) of the target compound 30 as a white solid (mp 128-129 °C): TLC (Merck; MeOH-CH₂Cl₂, 5:95, UV(+)) $R_f = 0.20$; ¹H-NMR (DMSO- d_6) δ 8.39 (d, J = 2.0 Hz, 1), 7.63 (dd, J = 8.0, 2.0 Hz, 1), 7.31 (d, J = 8.0Hz, 1), 7.04 (d, J = 8.6 Hz, 2), 6.77 (d, J = 8.6 Hz, 2), 4.75 (dd, J = 9.1, 4.3 Hz, 1), 4.22 (t, J = 6.5 Hz, 2), 3.97 (s, 2), 3.20 (dd, J = 14.1, 4.3 Hz, 1), 3.08 (t, J = 6.5 Hz, 2), 2.94 (dd, J = 14.1, 9.1 Hz, 1); IR (Nujol) 3027, 3011, 2712, 2604, 1761, 1742, 1708, 1516, 1469, 1330, 1251, 1232, 1187, 1040, 1019, 828, 736 cm⁻¹; EI/MS (70 eV) 367 (M⁺, 2.1), 251 (8.5), 223 (9.5), 145 (base), 132 (22.8); HRMS (EI) calcd for C₁₉H₁₇N₃O₃S (M⁺) 367.0991, found 367.0999.

5-(4-(2-(5-(Carboxymethyl)-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione (8). A stirring solution of 30 (0.404 g, 1.10 mmol) in 4 N aqueous HCl (20 mL) was heated under reflux for 18 h. The reaction mixture was cooled to room temperature, and the pH was adjusted to ca. 9 with 1 N aqueous NaOH. The solution was extracted with EtOAc (2 \times 25 mL), the aqueous layer was retained, and the pH was adjusted to ca. 5 with acetic acid. The resulting cloudy solution was extracted with EtOAc-MeOH (9:1; 5×30 mL), and the combined organic extracts were washed with brine (100 mL), dried (Na₂SO₄), and concentrated *in vacuo* to provide 0.31 g (72%) of 8 as a white, powdery solid (mp 146-148 °C): TLC (Merck; MeOH-CH₂Cl₂, 5:95, UV(+)) $R_f = 0.15$; ¹H-NMR (DMSO- d_6) δ 8.53 (d, J = 2.0 Hz, 1), 7.76 (dd, J = 7.9, 2.0 Hz, 1), 7.46 (d, J = 7.9 Hz, 1), 7.29 (d, J = 8.6 Hz, 2), 7.02 (d, J =8.6 Hz, 2), 4.99 (dd, J = 9.1, 4.3 Hz, 1), 4.47 (d, J = 6.6 Hz, 2), 3.75 (s, 2), 3.45 (dd, J = 14.1, 4.3 Hz, 1), 3.30 (t, J = 6.6 Hz, 2), 3.18 (dd, J = 14.1, 9.1 Hz, 1); IR (Nujol) 3438, 1693, 1641, 1581, 1515, 1252, 1165 cm⁻¹; FAB-MS 387 (M⁺+ 2H, base),

306 (6.0), 289 (8.5), 261 (6.0), 245 (6.5), 229 (22.7), 199 (9.9), 177 (17.6), 164 (54.7). Anal. $(C_{19}H_{18}N_2O_5S\cdot 0.37H_2O)$ C, H, N.

5-((4-(2-(5-Ethyl-2-pyridyl N-oxide)ethoxy)phenyl)methyl)-2,4-thiazolidinedione (31). To a suspension of **2.**0.33dioxane (48.5 g, 0.125 mol) in CH_2Cl_2 (1.2 L) was added methanol (0.3 L) followed by the addition of MCPBA (60%, 41.9 g, 0.145 mol) in one portion. The mixture was allowed to stir overnight at room temperature, affording a clear solution. The solution was cast into saturated aqueous NaHCO₃ (1 L); the organic phase was separated, washed with 10% aqueous Na₂S₂O₃ (0.75 L), saturated aqueous NaHCO₃ (1 L), and brine (1 L), and dried (Na₂SO₄). Concentration in vacuo afforded the crude product as a clear, colorless oil which slowly crystallized to furnish 31 (45.25 g, 96%) after drying in vacuo (40 °C). A portion of this material was recrystallized from acetonitrile to give 31.0.38CH₃CN as a white, highly crystalline solid (mp 160-161 °C): TLC (Merck; MeOH-CH₂Cl₂, 5:95, UV(+)) $R_f = 0.20$; ¹H-NMR (CDCl₃) δ 12.03 (brs, 1), 8.20 (d, J = 1.4 Hz, 1), 7.40 (d, J = 8.0 Hz, 1), 7.19 (dd, J = 8.0, 1.4 Hz, 1), 7.14 (d, J = 8.6 Hz, 2), 6.90 (d, J = 8.6 Hz, 2), 4.87 (dd, J= 9.1, 4.3 Hz, 1), 4.28 (t, J = 6.4 Hz, 2), 3.30 (dd, J = 14.2, 4.3 Hz, 1), 3.21 (d, J = 6.4 Hz, 2), 3.05 (dd, J = 14.2, 9.1 Hz, 1), 2.55 (q, J = 7.6 Hz, 2), 2.08 (s, CH₃CN), 1.16 (t, J = 7.6 Hz, 3); ¹³C-NMR (CDCl₃) δ 175.0, 171.2, 157.6, 146.2, 140.9, 138.9, 130.1, 128.2, 127.7, 126.6, 114.5, 63.6, 53.7, 37.7, 34.0, 30.7, 25.4, 14.3. Anal. (C19H20N2O4S·0.38CH3CN) C, H, N.

5-((4-(2-(5-Ethyl-2-pyridyl)-1-hydroxyethoxy)phenyl)methyl)-2,4-thiazolidinedione (9). A mixture of 31 (42.9 g, 115 mmol) and trifluoroacetic anhydride (81 mL, 121 g, 0.576 mol) in methylene chloride (0.5 L) was heated under reflux for 2 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was dissolved in THF (0.25 L), and saturated aqueous sodium bicarbonate was added slowly until gas evolution was no longer evident. Ethyl acetate and brine were added (0.25 L each), and the organic phase was separated. The aqueous phase was extracted with THF-EtOAc (1:1, 0.25 L), and the combined organic layers were washed with brine (0.5 L), dried (Na_2SO_4), and concentrated in vacuo to give crude 9 as a sticky, yellow solid. The crude product was purified by chromatography on a column of silica gel (500 g, 230-400 mesh, 70 mm o.d., CH₂Cl₂-acetone, 90: 10, 400 mL fractions) using the flash technique. Fractions 10-25 afforded 31.51 g (74%) of **9** as a free flowing white powder. Recrystallization from ethanol afforded 9.1/2EtOH as white needles (mp 128.4-130.4 °C): TLC (Merck; MeOH-CH₂Cl₂, 10:90, UV(+)) $R_f = 0.25$; ¹H-NMR (DMSO- d_6) δ 12.02 (brs, 1), 8.39 (d, J = 1.9 Hz, 1), 7.66 (dd, J = 8.0, 1.9 Hz, 1), 7.51 (d, J = 8.0 Hz, 1), 7.14 (d, J = 8.6 Hz, 2), 6.87 (d, J = 8.6 Hz, 2), 5.74 (d, J = 5.3 Hz, 1), 4.91 (m, 1), 4.86 (dd, J = 9.1, 4.4 Hz, 1), 4.25 (dd, J = 10.0, 4.4 Hz, 1), 4.06 (dd, J = 10.0, 9.1 Hz, 1), 3.44 (brq, J = 6.9 Hz, 1, EtOH), 3.29 (dd, J = 14.2, 4.3 Hz, 1), 3.04 (dd, J = 14.2, 9.0 Hz, 1), 2.61 (q, J = 7.5 Hz, 2), 1.19 (t, J = 7.5 Hz, 3), 1.05 (t, J = 6.9 Hz, 1.5, EtOH); ¹³C-NMR $(DMSO-d_6) \delta$ 175.6, 171.6, 158.5, 157.5, 147.8, 137.4, 135.7, 130.2, 128.5, 120.4, 114.3, 72.1, 71.8, 55.9, 52.9, 36.1, 24.9, 18.4, 15.3; IR (Nujol) 3530, 3030, 1760, 1737, 1705, 1513, 1332, 1241, 1231, 1180, 1160, 1106, 1053, 1038, 840, 732 cm⁻¹; EI/MS (70 eV) 372 (M⁺, 5.0), 355 (10), 325 (0.5), 210 (7), 150 (30), 136 (base). Anal. (C19H20N2O4S·0.5C2H5OH) C, H, N.

5-((4-(2-(5-Ethyl-2-pyridyl)-1-oxoethoxy)phenyl)methyl)-2,4-thiazolidinedione (10). To a solution of 9 (20.5 g, 55.0 mmol) in warm DMSO (50 mL) was added methylene chloride (450 mL), and the resulting solution was cooled in an ice-water bath. P₂O₅ (14.1 g, 99.0 mmol) was added in three portions over 0.5 h followed by the addition of triethylamine (19.5 g, 192 mmol, 27 mL) over 15 min. The mixture was allowed to stir for 2 h as it warmed to room temperature and then was concentrated in vacuo and the residue dissolved in THF (150 mL). The pH of the solution was adjusted to ca. 1 with 6 N aqueous HCl, and the mixture was allowed to stir for 1 h at room temperature. The solution was neutralized (pH ca. 7) with saturated aqueous sodium bicarbonate. The mixture was cast into ethyl acetate (0.5 L). The aqueous phase was extracted with EtOAc (0.5 L), and the combined organic layers were washed with brine (1.0 L) and dried (Na₂SO₄). Concentration in vacuo afforded the crude product 10 as a pale yellow foam which was purified by chromatography on a column of silica gel (500 g, 230–400 mesh, 70 mm o.d., CH₂Cl₂–acetone, 90:10, 400 mL fractions) using the flash technique. Fractions 5–15 afforded 17.97 g (88%) of **10** as a free flowing white powdery solid (mp 146–147 °C): TLC (Merck; MeOH–CH₂-Cl₂, 5:95, UV(+)) R_f = 0.21; ¹H-NMR (CDCl₃) δ 8.95 (brs, 1), 8.52 (d, J = 2.0 Hz, 1), 8.02 (d, J = 8.0 Hz, 1), 7.70 (dd, J = 8.0, 2.0 Hz, 1), 7.16 (d, J = 8.7 Hz, 2), 6.94 (d, J = 8.7 Hz, 2), 5.62 (s, 2), 4.49 (dd, J = 9.7, 3.8 Hz, 1), 3.47 (dd, J = 14.2, 3.8 Hz, 1), 3.08 (dd, J = 14.2, 9.7 Hz, 1), 2.76 (q, J = 7.6 Hz, 2), 1.31 (t, J = 7.6 Hz, 3); ¹³C-NMR (CDCl₃) δ 194.7, 174.1, 170.4, 157.7, 149.7, 148.9, 144.7, 136.3, 130.3, 128.4, 121.9, 115.2, 70.5, 53.7, 37.8, 26.4, 15.0; EI/MS (70 eV) 370 (M⁺, 19.4), 341 (6.9), 254 (20.6), 148 (base). Anal. (C₁₉H₁₈N₂O₄S) C, H, N, S.

References

- DeFronzo, R. A. The Triumvirate: the B-cell, Muscle, Liver. A Collusion Responsible for NIDDM. *Diabetes* 1988, 37, 667–687.
- (2) Reaven, G. M. Role of Insulin Resistance in the Pathophysiology of Non-Insulin-Dependent Diabetes Mellitus. *Diabetes/Metab. Rev.* 1993, 9, 5S-12S.
- Rubin, R. J.; Altman, W. M.; Mendelson, D. N. Health Care Expenditures for People with Diabetes Mellitus. *J. Clin. Endocrinol. Metab.* **1994**, *78*, 809A–809F.
 Reaven, G. M. Insulin Secretion and Insulin Action in Non-
- (4) Reaven, G. M. Insulin Secretion and Insulin Action in Non-Insulin-Dependent Diabetes Mellitus: Which Defect is Primary? *Diabetes Care* 1984, 7, 17–24.
- (5) Warram, J. H.; Martin, B. C.; Krolewski, A. S.; Soeldner, J. S.; Kahn, C. R. Slow glucose removal rate and hyperinsulinemia precede the development of Type II diabetes in the offspring of diabetic patients. *Ann. Int. Med.* **1990**, *113*, 909–915.
- (6) Colca, J. R. Potential antidiabetic drugs affecting the sensitivity of tissues to insulin. *Exp. Opin. Invest. Drugs* 1990, *3*, 857– 860.
- (7) See: Turner, N. C. New Therapeutic Agents for the Treatment of Insulin Resistance and NIDDM. *Drug Discovery Today* 1996, *1*, 109–116 and references cited therein.
- (8) Hofmann, C. A.; Colca, J. R. New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers. *Diabetes Care* 1992, 15, 1075–1078.
- (9) Weinstein, S. P.; Holand, A.; O'Boyle, E.; Haber, R. S. Effects of Thiazoldidinediones on Glucocorticoid-Induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. *Metabolism* **1993**, *42*, 1365–1369.
- (10) Iwanishi, M.; Kobayashi, M. Effect of Pioglitazone on Insulin Receptors of Skeletal Muscles from High-Fat-Fed Rats. *Metabolism* 1993, 42, 1017–1021.
- (11) Sugiyama, Y.; Taketomi, S.; Shimura, Y.; Ikeda, H.; Fujita, T. Effects of Pioglitazone on Glucose and Lipid Metabolism in Wistar Fatty Rats. *Arzneim.-Forsch./Drug Res.* 1990, 40, 263– 267.
- (12) Townes, R.; Kostyo, J.; Colca, J. Pioglitazone Inhibits the Diabetogenic Action of Growth Hormone, but Not Its Ability to Promote Growth. *Endocrinology* **1994**, *134*, 608–613.
- (13) Bleasdale, J. E.; Swanson, M. L. Hepatic Insulin Resistance in KKAy mice and its Amelioration by Pioglitazone do not Involve Alterations in Phospholipase C Activity. *Biochim. Biophys. Acta* **1993**, *1181*, 240–248.
- (14) Sizer, K. M.; Smith, C. L.; Jacob, C. S.; Swanson, M. L.; Bleasdale, J. E. Pioglitazone Promotes Insulin-Induced Activation of Phophoinositide 3-Kinase in 3T3-L1 Adipocytes by Inhibiting a Negative Control Mechanism. *Mol. Cell. Endocrinol.* **1994**, *102*, 119–129.
- (15) Kletzien, R. F.; Clarke, S. D.; Ulrich, R. G. Enhancement of Adipocyte Differentiation by an Insulin-Sensitizing Agent. *Mol. Pharmacol.* **1991**, *41*, 393–398.
- (16) Steiner, K. E.; Lien, E. L. Hypoglycemic agents which do not release insulin. *Prog. Med. Chem.* **1987**, *24*, 209.
- (17) Colca, J. R.; Morton, D. R. Antihyperglycemic thiazolidinediones: ciglitazone and its analogs. In *New Antidiabetic Drugs*, Bailey, C. J., Flatt, P. R., Eds.; Smith-Gordon: London, 1990; p 255.
- (18) Sohda, T.; Momose, Y.; Meguro, K.; Kawamatsu, Y.; Sugiyama, Y.; Ikeda, H. Studies on Antidiabetic Agents. Synthesis and Hypoglycemic Activity of 5-[4-(Pyridylalkoxy)-benzyl]-2,4-thiazolidinediones. Arzneim-Forsch./Drug Res. 1990, 40, 37-42.
- (19) Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on Hindered Phenols and Analogs. 1. Hypolipidemic and Hypoglycemic Agents with Ability To Inhibit Lipid Peroxidation. J. Med. Chem. 1989, 32, 421– 428.
- (20) Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.;

Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones as Hypoglycemic Agents. *J. Med. Chem.* **1991**, *34*, 319

- J. Med. Chem. 1991, 34, 319.
 (21) Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents. J. Med. Chem. 1992, 35, 1853–1864.
 (20) Gentherman M. A. Chem. The Construction of the Database of the Construction of the Construction of the Database of the Construction of th
- (22) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[\u03c6-(Heterocyclamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977–3985.
- (23) Zhong, W. Z.; Lakings, D. B. Determination of pioglitazone in dog serum using solid-phase extraction and high-performance liquid chromatography with ultraviolet (229 nm) detection. J. Chromatogr. 1989, 490, 377–385.
- (24) Loux, S. J.; Schuette, M. R.; Jone, B. W.; Rousch, K. E.; Greenfield, J. C. Disposition in rat of pioglitazone, a thiazolidinedione antidiabetic. *Abstr. Papers Am. Chem. Soc.* 1992, 204, P163-Medi.
- (25) Krieter, P. A.; Colletti, A. E.; Doss, G. A.; Miller, R. R. Disposition and Metabolism of the Hypoglycemic Agent Pioglitzaone in Rats. *Drug Metab. Dispos.* **1994**, *22*, 625–630.
- (26) Sohda, T.; Ikeda, H.; Meguro, K. Studies on Antidiabetic Agents. XII. Synthesis and Activity of the Metabolites of (+/-)-5[p[2[-(5-Ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (Pioglitazone). Chem. Pharm. Bull. 1995, 43, 2168–2172.
- (27) Frank, R. L.; Blegen, J. R.; Dearborn, R. J.; Myers, R. L.; Woodward, F. E. Pyridines. I. Aldehyde-collidine and 5-Ethyl-2-vinylpyridines. J. Am. Chem. Soc. **1946**, 68, 1368–1369.
- (28) Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triethylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1–28.

- (29) J. Huber, Pharmacia and Upjohn, Inc., Chemical Process Research and Development, Kalamazoo, MI, unpublished results; we thank Joel for sharing his work with us.
- (30) Leutenegger, U.; Madin, A.; Pfaltz, A. Enantioselective reduction of α,β-Unsaturated Carboxylates with NaBH₄ and Catalytic Amounts of Chiral Cobalt Semicorrin Complexes. *Angew. Chem.*, *Int. Ed. Engl.* 1989, *28*, 60–61.
- (31) Carlson, L. A.; Hedbom, C.; Helgstrand, E.; Misiorny, A.; Sjöberg, B.; Stejernström, N. E.; Westin, G. Potential hypolipidemic agents. IV. Syntheses of some halo-substituted pyridine compounds. Effects on noradrenaline-stimulated free fatty acid mobilization. *Acta Pharm. Seuc.* 1972, *9*, 411–418.
 (32) Boekelheide, V.; Linn, W. J. Rearrangements of N-Oxides. A
- (32) Boekelheide, V.; Linn, W. J. Rearrangements of N-Oxides. A Novel Synthesis of Pyridyl Carbinols and Aldehydes. J. Am. Chem. Soc. 1954, 76, 1286–1291.
- (33) Taber, D. F.; Amedio, J. C., Jr.; Jung, K.-Y. P₂O₅/DMSO/ Triethylamine (PDT): A Convenient Procedure for Oxidation of Alcohols to Ketones and Aldehydes. J. Org. Chem. 1987, 52, 5621-5622.
- (34) Hofmann, C.; Lorenz, K.; Colca, J. R. Glucose Transport deficiency in Diabetic Animals Is Corrected by Treatment with the Oral Antihyperglycemic Agent Pioglitazone. *Endocrinology* 1991, *129*, 1915–1925.
- (35) Iwatsuka, H.; Shino, A.; Suzuoki, Z. General Survey of Diabetic Features of Yellow KK Mice. *Endocrinol. Jpn.* **1970**, *17*, 23–25.
 (36) A registered trademark of Alpkem, Clackamas, OR.
- (37) Sohda, T.; Meguro, K.; Kawamatsu, Y. Studies on Antidiabetic Agents. IV. Synthesis and Activity of the Metabolites of 5-[4-(1-Methylcyclohexylmethoxybenzyl]-2,4-thiazolidinedione (Ciglitazone). Chem. Pharm. Bull. 1984, 32, 2267–2278.
- (38) Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923–2925.

JM9605694